SCHEMBL20548769

SCHEMBL20548769

C=CC(=O)Nc1cc(Nc2cc(Nc3cc(OC)c(Cl)cc3Cl)ncn2)c(OC)cc1CCCN1CCN(C)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 8/20 0.53
EGFR P00533 9/20 0.44
KDR P35968 2/20 0.44
ERBB2 P04626 2/20 0.43
FGFR4 P22455 3/20 0.42
FGFR2 P21802 1/20 0.42
FGFR3 P22607 1/20 0.42
JAK3 P52333 2/20 0.41
STK25 O00506 1/20 0.41
CIT O14578 1/20 0.41
RIOK3 O14730 1/20 0.41
MAP2K7 O14733 1/20 0.41
CHEK1 O14757 1/20 0.41
CASK O14936 1/20 0.41
GAK O14976 1/20 0.41
EPHB6 O15197 1/20 0.41
MAP3K13 O43283 1/20 0.41
MAP3K7 O43318 1/20 0.41
RIPK2 O43353 1/20 0.41
NUAK1 O60285 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL35210273 1.00 FGFR1 (0.53) FGFR1EGFRKDRERBB2FGFR4
SCHEMBL35210305 0.94 FGFR1 (0.47) FGFR1EGFRKDRFGFR4FGFR2
SCHEMBL20548767 0.94 FGFR1 (0.47) FGFR1EGFRKDRFGFR4FGFR2
SCHEMBL19089421 0.90 FGFR1 (0.55) FGFR1EGFRKDRERBB2JAK3
SCHEMBL35210289 0.87 FGFR1 (0.52) FGFR1EGFRKDRERBB2SRC
SCHEMBL19089420 0.87 FGFR1 (0.52) FGFR1EGFRKDRERBB2SRC
SCHEMBL19089427 0.84 EGFR (0.52) FGFR1EGFRKDRERBB2JAK3
SCHEMBL35210268 0.84 EGFR (0.60) FGFR1EGFRKCNH2ALK
SCHEMBL19089330 0.84 EGFR (0.60) FGFR1EGFRKCNH2ALK
SCHEMBL20548911 0.82 EGFR (0.56) FGFR1EGFRKDRFGFR4FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10342796-B2 Acrylanilide derivative, preparation method, and applications thereof in pharmacy ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) 2019-07-09 US claimed
US-20190015413-A1 ACRYLANILIDE DERIVATIVE, PREPARATION METHOD, AND APPLICATIONS THEREOF IN PHARMACY ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) 2019-01-17 US claimed
EP-3398939-A1 ACRYLANILIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN PHARMACY Ancureall Pharmaceutical (Shanghai) Co., Ltd. (CN) 2018-11-07 EP claimed
US-10342796-B2 Acrylanilide derivative, preparation method, and applications thereof in pharmacy ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) 2019-07-09 US disclosed
US-20190015413-A1 ACRYLANILIDE DERIVATIVE, PREPARATION METHOD, AND APPLICATIONS THEREOF IN PHARMACY ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) 2019-01-17 US disclosed
EP-3398939-A1 ACRYLANILIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN PHARMACY Ancureall Pharmaceutical (Shanghai) Co., Ltd. (CN) 2018-11-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10342796-B2 Acrylanilide derivative, preparation method, and applications thereof in pharmacy EGFR, ABL1, CSNK1A1 FGFR1 118/4885EGFR 1/4885KDR 1299/4885
US-20190015413-A1 ACRYLANILIDE DERIVATIVE, PREPARATION METHOD, AND APPLICATIONS THEREOF IN PHARMACY EGFR, ABL1, CSNK1A1 FGFR1 118/4885EGFR 1/4885KDR 1299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.